Exelixis: The FDA Delay Costs Less Than The Market Thinks (NASDAQ:EXEL)
· seekingalpha.com
The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. Read why EXEL stock is a Buy.
I do not like seeing the words "major amendment" in an FDA filing. They can describe a manageable request for more information, but they can also be the first p...